Literature DB >> 31695251

Molecular and Pathological Events Involved in the Pathogenesis of Diabetes-Associated Nonalcoholic Fatty Liver Disease.

Onkar Bedi1,2, Savera Aggarwal2, Nirupma Trehanpati2, Gayatri Ramakrishna1, Pawan Krishan1.   

Abstract

Diabetes mellitus is a rising epidemic in most part of the world and is often associated with multiple organ disorders such as kidney, liver, and cardiovascular diseases. Liver is a major metabolic hub, and the metabolic disorders associated with diabetes result in liver dysfunctions culminating in spectrum of liver diseases such as fatty liver disorders, cirrhosis, and hepatocellular carcinoma. The intervention strategies to prevent diabetes-associated liver injury require an overall understanding of the key factors and molecular pathways which can be strategically targeted. The present review focuses on some of the key aspects of fatty acid metabolism, fetuin-A regulation, inflammatory pathways, and genetic factors associated with insulin resistance, dyslipidemia, hyperglycemia, oxidative stress, and so on involved in the nexus between diabetes and liver injury. Further recent interventions, pharmacological target, and newer therapeutic agents are discussed briefly for the better clinical management of diabetes-associated hepatic disorders.
© 2018 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AP-1, Activator protein 1; DLI, diabetic liver injury; DM, diabetes mellitus; DMPs, Damage-associated molecular patterns; FFA, free fatty acid; FOXO1, Forkhead box protein O1; FetA, fetuin-A; G6Pase, Glucose-6-phosphatase; HCC, hepatocellular carcinoma; IKK, IκB kinase; IL, interleukin; IRS2, Insulin receptor substrate-2; IκB, Inhibitor of Kb; LPS, Lipopolysaccharide; MD2, Myeloid differentiation protein-2; MMP, matrix metalloproteinase; MyD88, Myeloid differentiation factor 88; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NFe κB, Nuclear factor-κB; NIDDM, noninsulin dependent diabetes mellitus; PC, Pyruvate carboxylase; PEPCK, Phosphoenolpyruvate carboxykinase; PIP3, Phosphatidyl inositol (3, 4, 5)-triphosphate; T2DM, type 2 diabetes mellitus; TLR4, Toll-like receptor; TNF, tumor necrosis factor; Th 17, T helper 17 cells; VLDL, very low–density lipoprotein; diabetes mellitus; diabetic liver injury; fetuin-A; free fatty acid; inflammatory mediators

Year:  2018        PMID: 31695251      PMCID: PMC6823706          DOI: 10.1016/j.jceh.2018.10.004

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  92 in total

1.  Human insulin receptor substrate-1 (IRS-1) polymorphism G972R causes IRS-1 to associate with the insulin receptor and inhibit receptor autophosphorylation.

Authors:  Aileen J McGettrick; Edward P Feener; C Ronald Kahn
Journal:  J Biol Chem       Date:  2004-12-07       Impact factor: 5.157

2.  Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice.

Authors:  Qi Gong; Zhimin Hu; Feifei Zhang; Aoyuan Cui; Xin Chen; Haoyang Jiang; Jing Gao; Xuqing Chen; Yamei Han; Qingning Liang; Dewei Ye; Lei Shi; Y Eugene Chin; Yu Wang; Hui Xiao; Feifan Guo; Yong Liu; Mengwei Zang; Aimin Xu; Yu Li
Journal:  Hepatology       Date:  2016-04-15       Impact factor: 17.425

3.  Insulin signalling and the regulation of glucose and lipid metabolism.

Authors:  A R Saltiel; C R Kahn
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

Review 4.  Adiponectin: a key player in obesity related disorders.

Authors:  Yuji Matsuzawa
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

5.  Prevention of hepatic fibrosis with liver microsomal triglyceride transfer protein deletion in liver fatty acid binding protein null mice.

Authors:  Elizabeth P Newberry; Yan Xie; Susan M Kennedy; Mark J Graham; Rosanne M Crooke; Hui Jiang; Anping Chen; Daniel S Ory; Nicholas O Davidson
Journal:  Hepatology       Date:  2017-01-19       Impact factor: 17.425

6.  Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies.

Authors:  John Willy Haukeland; Tuva B Dahl; Arne Yndestad; Ivar P Gladhaug; Else Marit Løberg; Terese Haaland; Zbigniew Konopski; Cecilie Wium; Erlend T Aasheim; Odd Erik Johansen; Pål Aukrust; Bente Halvorsen; Kåre I Birkeland
Journal:  Eur J Endocrinol       Date:  2011-12-14       Impact factor: 6.664

7.  Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Authors:  Bart Staels; Anne Rubenstrunk; Benoit Noel; Géraldine Rigou; Philippe Delataille; Lesley J Millatt; Morgane Baron; Anthony Lucas; Anne Tailleux; Dean W Hum; Vlad Ratziu; Bertrand Cariou; Rémy Hanf
Journal:  Hepatology       Date:  2013-10-29       Impact factor: 17.425

8.  Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance.

Authors:  David E Kelley; Therese M McKolanis; Refaat A F Hegazi; Lewis H Kuller; Satish C Kalhan
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-10       Impact factor: 4.310

9.  Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.

Authors:  Rachel M Williamson; Jackie F Price; Stephen Glancy; Elisa Perry; Lisa D Nee; Peter C Hayes; Brian M Frier; Liesbeth A F Van Look; Geoffrey I Johnston; Rebecca M Reynolds; Mark W J Strachan
Journal:  Diabetes Care       Date:  2011-04-08       Impact factor: 19.112

10.  Attenuation of hepatotoxicity and oxidative stress in diabetes STZ-induced type 1 by biotin in Swiss albino mice.

Authors:  Badr Abdullah Aldahmash; Doaa Mohamed El-Nagar; Khalid Elfakki Ibrahim
Journal:  Saudi J Biol Sci       Date:  2015-10-09       Impact factor: 4.219

View more
  10 in total

1.  In vitro targeted screening and molecular docking of stilbene, quinones, and flavonoid on 3T3-L1 pre-adipocytes for anti-adipogenic actions.

Authors:  Onkar Bedi; Savera Aggarwal; Nirupma Trehanpati; Gayatri Ramakrishna; Ajmer Singh Grewal; Pawan Krishan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-06-25       Impact factor: 3.000

Review 2.  Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation.

Authors:  Amedeo Lonardo; Alessandro Mantovani; Salvatore Petta; Amedeo Carraro; Christopher D Byrne; Giovanni Targher
Journal:  Nat Rev Endocrinol       Date:  2022-07-15       Impact factor: 47.564

3.  Pre-germinated brown rice alleviates non-alcoholic fatty liver disease induced by high fructose and high fat intake in rat.

Authors:  Pei-Wen Cheng; Hsin-Li Liang; Hui-Li Lin; Chi-Long Hao; Yu-Hsiu Tseng; Yi-Chen Tu; Bor-Chun Yeh; Kuo-Ping Shen
Journal:  J Clin Biochem Nutr       Date:  2022-03-24       Impact factor: 3.179

4.  Nonalcoholic Fatty Liver Disease: Lessons Learnt in the Last Five Years.

Authors:  Ajay Duseja; Radha K Dhiman; Madhumita Premkumar
Journal:  J Clin Exp Hepatol       Date:  2020-07-24

5.  Four weeks exercise training enhanced the hepatic insulin sensitivity in high fat- and high carbohydrate-diet fed hyperinsulinemic rats.

Authors:  Anu Joseph; S Parvathy; Koyikkal Karthikeya Varma; Aiswarya Nandakumar
Journal:  J Diabetes Metab Disord       Date:  2020-11-25

Review 6.  Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis.

Authors:  Chien-Yu Lin; Pratik Adhikary; Kun Cheng
Journal:  Adv Drug Deliv Rev       Date:  2021-04-20       Impact factor: 17.873

Review 7.  Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions.

Authors:  Maria Notarnicola; Alberto Ruben Osella; Maria Gabriella Caruso; Pasqua Letizia Pesole; Antonio Lippolis; Valeria Tutino; Caterina Bonfiglio; Valentina De Nunzio; Maria Principia Scavo; Antonella Mirizzi; Isabella Franco; Tamara Lippolis; Rosalba D'Alessandro; Maria Grazia Refolo; Caterina Messa
Journal:  Int J Mol Sci       Date:  2021-04-09       Impact factor: 5.923

8.  Repression of MicroRNA-124-3p Alleviates High-Fat Diet-Induced Hepatosteatosis by Targeting Pref-1.

Authors:  Guan Wang; Haibo Zou; Chunyou Lai; Xiaolun Huang; Yutong Yao; Guangming Xiang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-26       Impact factor: 5.555

9.  Total Bilirubin Predicts Severe Progression of Diabetic Retinopathy and the Possible Causal Mechanism.

Authors:  Yu Ding; Junmin Zhao; Gangsheng Liu; Yinglong Li; Jiang Jiang; Yun Meng; Tingting Xu; Kaifeng Wu
Journal:  J Diabetes Res       Date:  2020-07-31       Impact factor: 4.011

10.  The genetic association between type 2 diabetic and hepatocellular carcinomas.

Authors:  Zhan Shi; Zunqiang Xiao; Linjun Hu; Yuling Gao; Junjun Zhao; Yang Liu; Guoliang Shen; Qiuran Xu; Dongsheng Huang
Journal:  Ann Transl Med       Date:  2020-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.